Overweight: Clinical Trials

335 trials for Overweight, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

335 completed. 335 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4335Completed 335

Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight

Trials (filtered) newest first · largest first

All 335 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Calorie Restricted Dietary Intervention in Type 2 Diabetes Patients With Obesity for Remission
Contrave ER, Low-calorie meal box - Diabetes, Type 2, Obesity &Amp; Overweight
Phase 4CompletedYeouido St. Mary's Hospital252025-07-012026-08-07
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity
Piperacillin-tazobactam administered in a prolonged infusion, Piperacillin-tazobactam administered in a standard infusion - Infections, Obesity and Obesity-related Medical Conditions
Phase 4CompletedCR-CSSS Champlain-Charles-Le Moyne452025-02-262026-03-17
Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy (LSG)
Laparoscopic Sleeve Gastrectomy, gabapentin 1200 mg - Acute Kidney Injury, Obesity
Phase 4CompletedTanta University902024-12-012026-08-18
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
Empagliflozin-Metformin, Sitagliptin-Metformin, Metformin - Diabetes Mellitus, Type 2
Phase 4CompletedHawler Medical University1862024-11-152026-04-15
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin - Obesity, Overweight
Phase 4CompletedWW International Inc2262024-09-182026-04-13
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
GLP-1 medication - Diabetes Mellitus, Type 2, Obesity
Phase 4CompletedThe Cleveland Clinic692024-07-312025-12-05
Intermittent Phentermine for Obesity and Body Composition
Phentermine 15 MG, Phentermine 30 mg, Phentermine 37.5 Mg - Obesity & Overweight
Phase 4CompletedOSCAR MANUEL TORRES FALCON6002024-03-012026-10-13
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
Empagliflozin 10 MG, Insulin+Metformin+DPP4 inhibitor (DPP4I) - Glucose Metabolism Disorders, Diabetes Mellitus, Type 2
Phase 4CompletedSINA Health Education and Welfare Trust1502023-12-012024-04-08
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
Liraglutide injection, Diet and exercise guidelines - Obesity, Weight Loss
Phase 4CompletedThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1002023-09-012026-01-28
Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention - Obesity, Obesity, Abdominal
Phase 4CompletedChina National Center for Cardiovascular Diseases3372023-07-062025-01-29
The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
liraglutide, Low-calorie diet with dietician's monitoring - Obesity & Overweight
Phase 4CompletedMedical University of Bialystok832023-04-052026-11-03
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Semaglutide Injectable Product, Lifestyle Counseling - Aging, Diabetes Mellitus, Type 2
Phase 4CompletedThe University of Texas Health Science Center at San Antonio202023-04-012025-05-04
Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis
Cefazolin for Injection - Surgical Prophylaxis
Phase 4CompletedUniversity of Michigan572023-03-082026-01-30
Semaglutide in Nonalcoholic Fatty Liver Disease
Rybelsus Oral Product, Ozempic Injectable Product, Tocopherol and/or Actos - Non-alcoholic Fatty Liver Disease
Phase 4CompletedZagazig University1802023-02-152024-04-02
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Semaglutide, Orlistat, Phentermine/Topiramate - Obesity
Phase 4CompletedNovo Nordisk A/S5002023-01-192026-01-14
Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery
Liraglutide injection - Weight Loss, Bariatric Surgery Candidate
Phase 4CompletedHospital Civil Juan I. Menchaca372022-12-182024-01-18
Use of Empagliflozin to Treat Prediabetes
Empagliflozin, Multivitamin-Placebo - PreDiabetes, Prediabetic State
Phase 4CompletedOregon State University602022-10-132026-08-24
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
Ciprofol, Propofol - Gastric Ulcer, Gastric Cancer
Phase 4CompletedRenJi Hospital10902022-09-082024-06-07
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
Semaglutide, Placebo, Counselling on healthy lifestyle intervention - Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase 4CompletedMayo Clinic812022-09-062026-08-14
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
Semaglutide, Very Low Calorie Diet, Dietician counselling - Idiopathic Intracranial Hypertension, Intracranial Pressure
Phase 4CompletedRigmor Højland Jensen382022-09-022026-02-27

Showing 20 of 335. Sign in to see all of them.

Narrower conditions

Obesity (286)  ·  Diabetes Mellitus, Type 2 (33)  ·  Obesity, Morbid (33)  ·  Insulin Resistance (28)  ·  Weight Loss (28)  ·  Diabetes Mellitus (19)  ·  Hypertension (18)  ·  Metabolic Syndrome (17)  ·  Pediatric Obesity (14)  ·  Body Weight (12)  ·  Cardiovascular Diseases (11)  ·  Obesity, Abdominal (9)  ·  Hypogonadism (8)  ·  Inflammation (8)

Broader conditions

Nutritional and Metabolic Diseases (335)  ·  Nutrition Disorders (333)  ·  Overnutrition (333)  ·  Pathological Conditions, Signs and Symptoms (332)  ·  Signs and Symptoms (330)  ·  Body Weight (320)  ·  Metabolic Diseases (91)  ·  Glucose Metabolism Disorders (84)  ·  Endocrine System Diseases (73)  ·  Hyperinsulinism (38)  ·  Obesity (38)  ·  Diabetes Mellitus (37)  ·  Body Weight Changes (29)  ·  Cardiovascular Diseases (24)

Interventions

Liraglutide (32)  ·  Metformin (24)  ·  Phentermine (11)  ·  semaglutide (11)  ·  Qsymia (9)  ·  Exenatide (8)  ·  Injections (8)  ·  Propofol (8)  ·  Sodium Chloride (8)  ·  Diet (7)  ·  Orlistat (7)  ·  Sugars (7)  ·  Caloric Restriction (6)  ·  Solutions (6)  ·  Bupivacaine (5)

Sponsors

University Medical Centre Ljubljana (11)  ·  Mayo Clinic (7)  ·  Texas Tech University Health Sciences Center (6)  ·  University of Pennsylvania (6)  ·  Radboud University Medical Center (5)  ·  Henrik Gudbergsen (4)  ·  Hvidovre University Hospital (4)  ·  St. Antonius Hospital (4)  ·  The University of Texas Health Science Center, Houston (4)  ·  University of Texas Southwestern Medical Center (4)  ·  VIVUS LLC (4)  ·  Brigham and Women's Hospital (3)  ·  Centre Hospitalier Universitaire de Nīmes (3)  ·  Changi General Hospital (3)  ·  InQpharm Group (3)

Countries

United States (136)  ·  Denmark (17)  ·  Canada (16)  ·  Netherlands (14)  ·  China (10)  ·  France (10)  ·  Germany (10)  ·  Italy (10)  ·  Mexico (9)  ·  Slovenia (9)  ·  Brazil (6)  ·  Turkey (Türkiye) (6)  ·  Belgium (5)  ·  South Korea (5)  ·  Spain (5)

Top investigators

Ronald Hall, PharmD, MSCS (5)  ·  Andrej Janez, MD, PhD (4)  ·  Eda Vrtacnik Bokal, professor (3)  ·  Holly Wyatt, MD (3)  ·  James Hill, PhD (3)  ·  Samuel Klein, MD (3)  ·  Alison Edelman, MD, MPH (2)  ·  Andrej Janez, MD PhD (2)  ·  Eleftheria Maratos-Flier, MD (2)  ·  Gary Foster, PhD (2)  ·  Manjunath P Pai, PharmD (2)

Results publications

PMID 28143456, PMID 10527182, PMID 11010931, PMID 11282917, PMID 11454256, PMID 11502778, PMID 11696118, PMID 11836290, PMID 12046553, PMID 12195709, PMID 12540646, PMID 12550060, PMID 12590412, PMID 14688154, PMID 15321413, PMID 15459601, PMID 15482620, PMID 15853597, PMID 15867308, PMID 16443140, PMID 16481154, PMID 16539090, PMID 16960170, PMID 16960171, PMID 17125535, PMID 17126774, PMID 17360978, PMID 17585226, PMID 17595249, PMID 17766923, PMID 17850473, PMID 17875948, PMID 18173431, PMID 18695075, PMID 18725220, PMID 18761646, PMID 18996858, PMID 19018785, PMID 19053049, PMID 19116237, PMID 19125756, PMID 19176282, PMID 19263591, PMID 19300114, PMID 19321572, PMID 19357147, PMID 19383731, PMID 19411667, PMID 19447599, PMID 19482214

NIH funding

5UL1RR024982-02 (5), 2015 (2), 2017 (2), 2019 (2), R01AT001103 (2), R01DK067071 (2), UL1TR000135 (2), 2005 (1), 2008 (1), 2009 (1), 2016 (1), K12HD057022 (1), K23DK095913 (1), K23DK106520 (1), K23DK115827 (1)